Indications Nastor tablet is indicated for:

Patients with primary hyperlipidemia and mixed dyslipidemia as an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, non-HDL-C, and TG levels, and to increase HDL-C.
Patients with hypertriglyceridemia as an adjunct to diet.
Patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet.
Patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C, and ApoB.
Slowing the progression of atherosclerosis as part of a treatment strategy to lower total-C and LDL-C as an adjunct to diet.
Pediatric patients 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total-C, LDL-C, and ApoB after failing an adequate trial of diet therapy.
Risk reduction of myocardial infarction (MI), stroke, and arterial revascularization procedures in patients without clinically evident CHD but with multiple risk factors.

Pharmacology Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol. Rosuvastatin produces its lipid-modifying effects in two ways:

It increases the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL.
It inhibits hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.

Dosage & Administration

Pediatric patients (10–17 years, HeFH): Usual dose range 5–20 mg/day; maximum 20 mg/day.
Very high cholesterol and high risk of MI or stroke: 40 mg once daily.
Homozygous familial hypercholesterolemia: Recommended starting dose 20 mg once daily.
Asian patients: Initiation with 5 mg once daily should be considered.
With cyclosporine: Limit dose to 5 mg once daily.
With lopinavir/ritonavir or atazanavir/ritonavir: Limit dose to 10 mg once daily.
Concomitant lipid-lowering therapy: Risk of muscle effects may be increased with niacin or fenofibrate; dose reduction should be considered. Avoid combination with gemfibrozil; if used, limit dose to 10 mg once daily.
Severe renal impairment: Start at 5 mg once daily, do not exceed 10 mg/day.

Interactions

Cyclosporine: Increases exposure; limit dose to 5 mg/day.
Gemfibrozil: Avoid; if used, limit dose to 10 mg/day.
Lopinavir/ritonavir or atazanavir/ritonavir: Increases exposure; limit dose to 10 mg/day.
Coumarin anticoagulants: May prolong INR; monitor closely.
Concomitant fibrates or niacin: May increase risk of muscle effects.

Contraindications

Hypersensitivity to product components
Active liver disease, including unexplained persistent elevations of hepatic transaminases
Pregnant women or women who may become pregnant
Nursing mothers

Side Effects Nastor is generally well tolerated. The most frequent adverse events include headache, myalgia, constipation, asthenia, abdominal pain, and nausea.